Dendreon (DNDN) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS
Dendreon (NASDAQ:DNDN) posted its quarterly earnings results on Monday. The company reported ($0.10) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.25) by $0.15, Analyst Ratings Net reports. The company had revenue of $82.16 million for the quarter, compared to the consensus estimate of $73.37 million. During the same quarter in the prior year, the company posted ($0.45) earnings per share. The company’s quarterly revenue was up 12.1% on a year-over-year basis.
Dendreon (NASDAQ:DNDN) traded up 4.95% on Monday, hitting $2.12. 2,344,835 shares of the company’s stock traded hands. Dendreon has a 52 week low of $1.81 and a 52 week high of $3.52. The stock has a 50-day moving average of $2.16 and a 200-day moving average of $2.49. The company’s market cap is $328.8 million.
On a related note, analysts at Zacks reiterated a “neutral” rating on shares of Dendreon in a research note on Friday, July 18th. They now have a $2.25 price target on the stock. Seven investment analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. Dendreon presently has an average rating of “Hold” and an average target price of $2.67.
Dendreon Corporation (NASDAQ:DNDN) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.